Lobbying client

REPLIMUNE

Biotech company focused on resolution of cancer treatment.

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 4 of its records are shown together here.

Filings
20
Filed by
4
Reported in-house
—
Reported by firms
$900,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2025 to 2026

Filings

20 filings, newest first.
Filing Filed by Amount
3rd Quarter - Amendment
3rd Quarter 2026
TARPLIN, DOWNS & YOUNG, LLC $60,000 reported
3rd Quarter - Reportreplaced
3rd Quarter 2026
TARPLIN, DOWNS & YOUNG, LLC $60,000 reported
3rd Quarter - Report
3rd Quarter 2026
CHECKMATE GOVERNMENT RELATIONS $120,000 reported
2nd Quarter - Report
2nd Quarter 2026
TARPLIN, DOWNS & YOUNG, LLC $60,000 reported
1st Quarter - Termination
1st Quarter 2026
FARRAGUT PARTNERS LLP $60,000 reported
2nd Quarter - Report
2nd Quarter 2026
CHECKMATE GOVERNMENT RELATIONS $100,000 reported
2nd Quarter - Termination
2nd Quarter 2026
AXADVOCACY GOVERNMENT RELATIONS $20,000 reported
Registration
2nd Quarter 2026
CHECKMATE GOVERNMENT RELATIONS — reported
1st Quarter - Report
1st Quarter 2026
TARPLIN, DOWNS & YOUNG, LLC $60,000 reported
1st Quarter - Report
1st Quarter 2026
AXADVOCACY GOVERNMENT RELATIONS $60,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 18
Medical/Disease Research/Clinical Labs MED 3

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.